Including males in Canadian human papillomavirus vaccination programs: a policy analysis

The Canadian National Advisory Committee on Immunization (NACI) recommends human papillomavirus (HPV) vaccination for females aged 9–26 years (bivalent or quadrivalent vaccine) and males aged 9–26 years (quadrivalent vaccine) ([Figure 1][1]).[1][2] All Canadian provinces and territories